Meghan Thompson, MD

Meghan Thompson, MD, discusses the rationale for the phase 1/2 BRUIN study in patients with Richter transformation. 

Meghan Thompson, MD, discusses the safety profile of pirtobrutinib in patients with Richter transformation.

Meghan Thompson, MD, discusses the results of the phase 1/2 BRUIN study in patients with Richter transformation.

Meghan Thompson, MD, discusses the evolving role of minimal residual disease testing in chronic lymphocytic leukemia.

Meghan Thompson, MD, discusses future research directions in chronic lymphocytic leukemia.

Meghan Thompson, MD, discusses emerging treatment strategies with BTK inhibitors in chronic lymphocytic leukemia.